Can a bone marrow stimulant help people with leg artery disease walk farther?
NCT ID NCT03304821
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested whether a drug called GM-CSF can improve symptoms and blood flow in people with peripheral artery disease (PAD), a condition where plaque narrows leg arteries, causing pain and limiting walking. 151 participants received either GM-CSF or a placebo for two 3-week treatment periods. The main goal was to see if GM-CSF increased the distance they could walk in 6 minutes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GM-CSF (also called Sargramostim or Leukine)
What this could lead to
If it works, this could point toward a treatment that improves walking ability and blood flow in people with peripheral artery disease.
What could go wrong
This is a Phase 2 trial with 151 participants, so results are still early. The drug may not show significant benefit over placebo, and side effects like injection site reactions or bone pain are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERY DISEASE (PAD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital
Atlanta, Georgia, 30322, United States